Health TrialsbyHealthPanel

PET/MR in the Staging and Efficacy Evaluation of Newly Diagnosed NK/T-cell Lymphoma

ConditionNK/T-cell Lymphoma
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age14-70
SponsorRuijin Hospital

About this trial

This study intends to evaluate the application value of Positron Emission Tomography/Magnetic Resonance (PET/MR) in the staging and efficacy evaluation of NK/T cell lymphoma, aiming to explore a more accurate system for predicting the prognosis of patients and guiding the treatment.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Pathologically diagnosed NK/T-cell lymphoma based on the WHO classification 2016

Age from 14 to 70 years-old

ECOG 0-2 score

Patients with a life expectancy of at least 6 months

Disqualifiers

Diagnosed aggressive NK cell leukemia

Pregnant or lactating women

Liver and kidney insufficiency

Those with implanted functional electronic devices such as cardiac pacemakers

Trial design

Design model

Single group

Treatments tested in this trial

  • Positron Emission Tomography/Magnetic Resonance (PET/MR)

    Device

    18F-FDG PET/MR imaging (manufacturer: Siemens, model: Biography mMR). Research devices are marketed products.

Treatment groups

40 Participants
are divided into 1 treatment group
Group A: PET/MRExperimental treatment 1 intervention

Trial outcomes

Primary outcomes

1

The sensitivity, specificity and accuracy of PET/MR in the staging of newly diagnosed NK/T-cell lymphoma patients

SUVmax, organs, et al.

Time frame
Baseline
2

The sensitivity, specificity and accuracy of PET/MR in the efficacy evaluation of newly diagnosed NK/T-cell lymphoma patients

SUVmax, organs, et al.

Time frame
After at least 2 cycles

Secondary outcomes

1

Exploratory construction of prognostic prediction or efficacy evaluation system for newly treated NK/T-cell lymphoma based on PET/MR imaging indicators.

SUVmax, organs, progression-free survival, overall survival, et al.

Time frame
Baseline up to data cut-off (up to approximately 4 years)

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Ruijin Hospital

Lead sponsor

Source ClinicalTrials.gov
Apply now